Glaxosmithkline Patient Access Programs Foundation
Glaxosmithkline Patient Access Programs Foundation consistently disburses 100% of revenue to programs with no reported officer compensation.
EIN: 200031992 · Philadelphia, PA · NTEE: T23 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $1.1B |
| Total Expenses | $903.0M |
| Program Spending | 100% |
| Net Assets | $0 |
| Transparency Score | 95/100 |
Is Glaxosmithkline Patient Access Programs Foundation Legit?
Appears Legitimate
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Glaxosmithkline Patient Access Programs Foundation directs 100% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Glaxosmithkline Patient Access Programs Foundation
Glaxosmithkline Patient Access Programs Foundation (EIN: 200031992) is a nonprofit organization based in Philadelphia, PA, classified under NTEE code T23. The organization reported total revenue of $1.1B and total assets of $85.3M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Glaxosmithkline Patient Access Programs Foundation's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Glaxosmithkline Patient Access Programs Foundation is a major nonprofit that has been operating for 22 years, with 9 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 3.1%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $903.0M |
| Total Expenses | $903.0M |
| Surplus / Deficit | +$0 |
| Total Assets | $73.5M |
| Total Liabilities | $73.5M |
| Net Assets | $0 |
| Operating Margin | 0.0% |
| Debt-to-Asset Ratio | 100.0% |
| Months of Reserves | 1.0 months |
Financial Health Grade: C
In 2023, Glaxosmithkline Patient Access Programs Foundation reported a surplus of $0 with revenue exceeding expenses, holds 1.0 months of operating reserves (limited), has a debt-to-asset ratio of 100.0% (high leverage).
Financial Trends
Over 9 years of filings (2011–2023), Glaxosmithkline Patient Access Programs Foundation's revenue has grown at a compound annual growth rate (CAGR) of 3.1%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +15.0% | +15.0% | +15.5% |
| 2022 | +27.9% | +27.9% | +29.1% |
| 2021 | +16.3% | +16.3% | +17.0% |
| 2020 | +8.4% | +8.4% | +8.8% |
| 2019 | -15.8% | -15.8% | -15.8% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2004 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Glaxosmithkline Patient Access Programs Foundation with a Mission Score of 95 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 0%
- programs: 100%
- fundraising: 0%
According to IRS 990 filings, Glaxosmithkline Patient Access Programs Foundation allocates its expenses as follows: admin: 0%, programs: 100%, fundraising: 0%. With 100% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $0, with revenue exceeding expenses.
- Debt-to-asset ratio: 100.0%.
Executive Compensation Analysis
The organization reports 0% officer compensation across all available filings, indicating that executive leadership is either unpaid or compensated by an affiliated entity, which is a strong positive for direct program spending efficiency.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Strengths
The following positive indicators were identified for Glaxosmithkline Patient Access Programs Foundation:
- 100% program spending ratio, with expenses consistently matching revenue across all filings.
- No reported officer compensation, indicating high efficiency and dedication to mission.
- Significant and growing revenue, exceeding $1 billion in the latest period, demonstrating substantial impact.
- Consistent financial transparency with assets always equaling liabilities, suggesting a clear pass-through model.
Frequently Asked Questions about Glaxosmithkline Patient Access Programs Foundation
Is Glaxosmithkline Patient Access Programs Foundation a legitimate charity?
Based on AI analysis of IRS 990 filings, Glaxosmithkline Patient Access Programs Foundation (EIN: 200031992) appears legitimate. Mission Score: 95/100. 0 red flags identified, 4 strengths noted.
How does Glaxosmithkline Patient Access Programs Foundation spend its money?
Glaxosmithkline Patient Access Programs Foundation directs 100% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Glaxosmithkline Patient Access Programs Foundation tax-deductible?
Glaxosmithkline Patient Access Programs Foundation is registered as a tax-exempt nonprofit (EIN: 200031992). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How does Glaxosmithkline Patient Access Programs Foundation compare to similar nonprofits?
With a transparency score of 95/100 (Excellent), Glaxosmithkline Patient Access Programs Foundation is above average for NTEE category T23 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Glaxosmithkline Patient Access Programs Foundation located?
Glaxosmithkline Patient Access Programs Foundation is headquartered in Philadelphia, Pennsylvania and files with the IRS under EIN 200031992. It is classified under NTEE code T23.
How many years of IRS 990 filings does Glaxosmithkline Patient Access Programs Foundation have?
Glaxosmithkline Patient Access Programs Foundation has 9 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $1.1B in total revenue.
Is Glaxosmithkline Patient Access Programs Foundation a good charity?
Based on the available IRS 990 data, the foundation appears to be highly effective in its mission, consistently spending 100% of its revenue on programs and reporting no officer compensation. This indicates excellent financial efficiency and a strong focus on its programmatic goals.
How does the foundation manage its finances given revenue equals expenses?
The consistent reporting of revenue equaling expenses suggests a direct pass-through model where funds are immediately disbursed for patient access programs. This implies a highly efficient operational model with minimal overhead or retained earnings.
What is the source of the foundation's substantial revenue?
While the filings don't explicitly detail the source, given the name 'Glaxosmithkline Patient Access Programs Foundation,' it is highly probable that the primary source of revenue is from GlaxoSmithKline itself, funding patient assistance initiatives.
Filing History
IRS 990 filing history for Glaxosmithkline Patient Access Programs Foundation showing financial trends over 9 years of public records:
Over 9 years of IRS 990 filings (2011–2023), Glaxosmithkline Patient Access Programs Foundation's revenue has grown by 44%, moving from $627.2M to $903.0M. Total assets increased by 48.6% over the same period, from $49.5M to $73.5M. Total functional expenses rose by 44%, from $627.2M to $903.0M. In its most recent filing year (2023), Glaxosmithkline Patient Access Programs Foundation reported a surplus of $0, with revenue exceeding expenses. The organization holds $73.5M in liabilities against $73.5M in assets (debt-to-asset ratio: 100.0%), resulting in net assets of $0.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $903.0M | $903.0M | $73.5M | $73.5M | — | View 990 |
| 2022 | $784.9M | $784.9M | $63.6M | $63.6M | — | View 990 |
| 2021 | $613.6M | $613.6M | $49.3M | $49.3M | — | View 990 |
| 2020 | $527.5M | $527.5M | $42.1M | $42.1M | — | View 990 |
| 2019 | $486.6M | $486.6M | $38.7M | $38.7M | — | — |
| 2014 | $577.9M | $577.9M | $46.0M | $46.0M | — | View 990 |
| 2013 | $645.1M | $645.1M | $51.4M | $51.4M | — | View 990 |
| 2012 | $620.5M | $620.5M | $47.9M | $47.9M | — | View 990 |
| 2011 | $627.2M | $627.2M | $49.5M | $49.5M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $903.0M, expenses of $903.0M, and assets of $73.5M (revenue +15.0% year-over-year).
- 2022: Revenue of $784.9M, expenses of $784.9M, and assets of $63.6M (revenue +27.9% year-over-year).
- 2021: Revenue of $613.6M, expenses of $613.6M, and assets of $49.3M (revenue +16.3% year-over-year).
- 2020: Revenue of $527.5M, expenses of $527.5M, and assets of $42.1M (revenue +8.4% year-over-year).
- 2019: Revenue of $486.6M, expenses of $486.6M, and assets of $38.7M (revenue -15.8% year-over-year).
- 2014: Revenue of $577.9M, expenses of $577.9M, and assets of $46.0M (revenue -10.4% year-over-year).
- 2013: Revenue of $645.1M, expenses of $645.1M, and assets of $51.4M (revenue +4.0% year-over-year).
- 2012: Revenue of $620.5M, expenses of $620.5M, and assets of $47.9M (revenue -1.1% year-over-year).
- 2011: Revenue of $627.2M, expenses of $627.2M, and assets of $49.5M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Glaxosmithkline Patient Access Programs Foundation:
Data Sources and Methodology
This transparency report for Glaxosmithkline Patient Access Programs Foundation is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.